Regulation of cell adhesion by PAI-1

APMIS

Volumn 107, Issue 1, 1999, Pages 54-61

  Loskutoff, David J ^a   Curriden, Scott A ^a   Hu, Geng ^a   Deng, Gang ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cell adhesion; Integrins; Type I plasminogen activator inhibitor (PAI 1); Urokinase plasminogen activator receptor (uPAR); Vitronectin (VN)

Indexed keywords

INTEGRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR; VITRONECTIN;

BINDING COMPETITION; BINDING SITE; CELL ADHESION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW;

EID: 0033003218     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01526.x     Document Type: Review

References (56)

1. 1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
2. 2. Loskutoff DJ, Sawdey M, Mimuro J. Coller B, editors. Progress in Hemostasis and Thrombosis. 9th ed. Philadelphia: WB. Saunders Company; 1989; Type 1 plasminogen activator inhibitor. p. 87-115.
3. 3. Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991;1:99-102.
4. 4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44:139-266.
5. 5. Vassalli JD, Sappino A, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
6. 3 binding to vitronectin. Nature 1996;383:441-3.
7. 7. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71.
8. 8. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein in endothelial cells. Exp Cell Res 1996;224:344-53.
9. 9. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9.
10. 10. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997;100:58-67.
11. 11. Stefansson S, Haudenschild CC, Lawrence DA. Beyond fibrinolysis: The role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 1998;8:175-80.
12. 12. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Current Opinion in Cell Biology 1997;9:714-24.
13. 13. Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 1998;252:185-93.
14. 14. Carrell R, Travis J. a-1-Antitrypsin and the serpins: Variation and countervariation. Trends Biochem Sci 1985;10:20-4.
15. 15. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985;260:11581-7.
16. 16. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Berhaus GM, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988;30:15454-61.
17. 17. Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988;242:125-8.
18. 18. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: Evidence that the protein is vitronectin. J Biol Chem 1989;264:936-9.
19. 19. Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987;70:721-8.
20. 20. Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 1995;9:263-76.
21. 21. Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Muller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265:18490-9.
22. 22. Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990;111:1283-91.
23. 23. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994;269:15223-8.
24. 24. Ehrlich HJ, Gebbink RK, Keijer J, Pannekoek H. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 1992;267:11606-11.
25. 25. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992;355:270-3.
26. 26. Nakashima N, Miyazaki K, Ishikawa M, Yatohgo T, Ogawa H, Uchibori H, Matsumoto I, Seno N, Hayashi M. Vitronectin diversity in evolution but uniformity in ligand binding and size of the core polypeptide. Biochim Biophys Acta 1992;1120:1-10.
27. 27. Fryklund L, Uthne K, Sievertsson H, Kabi AB. Isolation and characterization of polypeptides from human plasma enhancing the growth of human normal cells in culture. Biochem Biophys Res Commun 1974;61:950-6.
28. 28. Heldin C, Wasteson A, Fryklund L, Westermark B. Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. Science 1981;213:1122-3.
29. 29. Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985;4:2519-24.
30. 30. Tomasini BR, Mosher DF. Coller BS, editors. Progress in Hemostasis and Thrombosis. 10th ed. Philadelphia: W. B. Saunders; 1990; Vitronectin. p. 269-305.
31. 31. Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992;267:12098-105.
32. 32. Salonen E, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;264:6339-43.
33. 33. Sigurdardottir O, Wiman B. Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin. Fibrinolysis 1992;6:27-32.
34. 34. Seiffert D, Loskutoff DJ. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim Biophys Acta 1991;1078:23-30.
35. 35. Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991;266:2824-30.
36. 36. Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, Sakata Y. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry 1993;32:2314-20.
37. 37. Audenaert A-M, Knockaert I, Collen D, Declerck PJ. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem 1994;269:19559-64.
38. 38. Deng G, Royle G, Seiffert D, Loskutoff D. The PAI-1/vitronectin interaction: Two cats in a bag? Thromb Haemostas 1995;74:66-70.
39. 39. Gechtman Z, Sharma R, Kreizman T, Fridkin M, Shaltiel S. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin: Use in mapping the PAI-1 binding site. FEBS Lett 1993;315: 293-7.
40. 40. Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: Implications for the regulation of pericellular proteolysis. J Biol Chem 1997;272:7676-80.
41. 41. Seiffert D. The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin. J Biol Chem 1997;272:9971-8.
42. 42. Seiffert D, Smith JW. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 1997;272: 13705-10.
43. 43. Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994;1208:104-10.
44. 44. Seiffert D, Ciambrone G, Wagner NV, Binder BB, Loskutoff DJ. The somatomedin B domain of vitronectin: Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994;269:2659-66.
45. 45. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 1996;271:12716-23.
46. 46. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991;88:9402-6.
47. 47. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994;269:14746-50.
48. 48. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
49. 49. Cubellis MV, Wun T, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-85.
50. 2 macroglobulin receptor/Ld1 receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995;131:1609-22.
51. 51. Knudsen BS, Hapel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987;80:1082-9.
52. 52. Chain D, Kreizman T, Shapira H, Shaltiel S. Plasmin cleavage of vitronectin: Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 1991;285:251-6.
53. 53. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997;71:116-22.
54. 54. Preissner KT, Potzsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. Histol Histopathol 1995;10:239-51.
55. 55. Loridon-Rosa B, Vielh P, Cuadrado C, Burtin P. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol 1988;90:7-16.
56. 56. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-32.